Skyepharma has announced the launch of Flutiform fluticasone/formoterol MDI for the treatment of asthma in France. Mundipharma will market the inhaler in 50/5 µg and 125/5 µg versions. The launch triggers a €3.0 million milestone payment from Mundipharma to Skyepharma.
Flutiform was approved by the European Commission in 2012 and has now been launched in 14 countries in Europe, as well as in Hong Kong, Australia, and Japan.
Skyepharma CEO Peter Grant said, “With the launch in France and the recent successful completion of the mutual recognition procedure for Spain, Flutiform is now on track to be available in all of Europe’s five largest markets, bringing more patients an effective treatment for asthma. We look forward to the further roll-out of Flutiform and its continued growth.”
Read the Skyepharma press release.
